MY210519A - Modulation of t cell responses by ul18 of human cytomegalovirus - Google Patents

Modulation of t cell responses by ul18 of human cytomegalovirus

Info

Publication number
MY210519A
MY210519A MYPI2022000951A MYPI2022000951A MY210519A MY 210519 A MY210519 A MY 210519A MY PI2022000951 A MYPI2022000951 A MY PI2022000951A MY PI2022000951 A MYPI2022000951 A MY PI2022000951A MY 210519 A MY210519 A MY 210519A
Authority
MY
Malaysia
Prior art keywords
cell responses
human cytomegalovirus
modulation
mhc
methods
Prior art date
Application number
MYPI2022000951A
Other languages
English (en)
Inventor
Louis J Picker
Daniel Malouli
Scott G Hansen
Klaus J Frueh
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74660048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY210519(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of MY210519A publication Critical patent/MY210519A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
MYPI2022000951A 2019-08-20 2020-08-19 Modulation of t cell responses by ul18 of human cytomegalovirus MY210519A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889310P 2019-08-20 2019-08-20
PCT/US2020/047050 WO2021034964A1 (en) 2019-08-20 2020-08-19 Modulation of t cell responses by ul18 of human cytomegalovirus

Publications (1)

Publication Number Publication Date
MY210519A true MY210519A (en) 2025-09-29

Family

ID=74660048

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022000951A MY210519A (en) 2019-08-20 2020-08-19 Modulation of t cell responses by ul18 of human cytomegalovirus

Country Status (19)

Country Link
US (1) US20220307054A1 (enExample)
EP (1) EP4017985A4 (enExample)
JP (2) JP7693651B2 (enExample)
KR (1) KR20220047619A (enExample)
CN (1) CN114402080B (enExample)
AU (1) AU2020334061B2 (enExample)
BR (1) BR112022003159A2 (enExample)
CA (1) CA3148642A1 (enExample)
CL (1) CL2022000398A1 (enExample)
CO (1) CO2022002922A2 (enExample)
CR (1) CR20220093A (enExample)
DO (1) DOP2022000041A (enExample)
EC (1) ECSP22013145A (enExample)
IL (1) IL290748A (enExample)
MX (1) MX2022002154A (enExample)
MY (1) MY210519A (enExample)
PE (1) PE20220648A1 (enExample)
PH (1) PH12022550439A1 (enExample)
WO (1) WO2021034964A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240384296A1 (en) * 2021-08-31 2024-11-21 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
WO2024059635A2 (en) * 2022-09-13 2024-03-21 Oregon Health And Science University Universal t cell-based, cmv-vectored vaccine for influenza

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1410314A (en) 1920-11-04 1922-03-21 Edgar B Hyatt Garage-door control
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US20020069244A1 (en) 1999-11-24 2002-06-06 John Blair Message delivery system billing method and apparatus
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2074747B1 (en) 2006-09-28 2015-08-05 PacketFront Network Products AB Method for automatically providing a customer equipment with the correct service
DE112013006773T5 (de) 2013-03-06 2015-12-10 SiEVA Vorrichtung für high-side Transistor-Brückentreiber
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
EA201791806A1 (ru) * 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
AU2017280065B2 (en) * 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018075591A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Also Published As

Publication number Publication date
CA3148642A1 (en) 2021-02-25
AU2020334061A1 (en) 2022-03-10
AU2020334061B2 (en) 2026-06-11
MX2022002154A (es) 2022-03-17
KR20220047619A (ko) 2022-04-18
CO2022002922A2 (es) 2022-04-19
WO2021034964A1 (en) 2021-02-25
JP2025131719A (ja) 2025-09-09
CN114402080B (zh) 2024-09-13
EP4017985A1 (en) 2022-06-29
EP4017985A4 (en) 2023-09-27
PH12022550439A1 (en) 2023-03-13
JP2022544704A (ja) 2022-10-20
BR112022003159A2 (pt) 2022-05-17
US20220307054A1 (en) 2022-09-29
IL290748A (en) 2022-04-01
CR20220093A (es) 2022-06-15
NZ785288A (en) 2025-09-26
JP7693651B2 (ja) 2025-06-17
ECSP22013145A (es) 2022-04-29
CN114402080A (zh) 2022-04-26
CL2022000398A1 (es) 2023-03-17
PE20220648A1 (es) 2022-04-28
DOP2022000041A (es) 2022-08-15

Similar Documents

Publication Publication Date Title
WO2017066561A3 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2020002530A (es) Indicacion de haces para control de potencia de enlace ascendente.
TN2019000124A1 (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
GEP20237572B (en) Polyheterocyclic modulators of sting (stimulator of interferon genes)
EP3941123A3 (en) Uplink transmissions for dual connectivity
EP2224921A4 (en) MODULATION OF THE IMMUNE RESPONSE
EP3319376A3 (en) Method and apparatus for triggering power headroom report for beam operation in a wireless communication system
MX2020001833A (es) Moduladores de piruvato quinasas y uso de los mismos.
MX2014008397A (es) Refractometro con un generador de frente de onda remoto.
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020008106A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
MX2019008844A (es) Ingenieria de celulas b.
PH12022550439A1 (en) Modulation of t cell responses by ul18 of human cytomegalovirus
HK1247958A1 (zh) T淋巴细胞的调节
WO2015157778A3 (en) System and method for generating high energy optical pulses with arbitrary waveform
AU2017254665A1 (en) Compositions and methods for enhanced gene expression of pklr
WO2020223381A3 (en) Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same
EP4252681A3 (en) Implantable objects, guiding devices, and methods of use thereof
GB201705650D0 (en) Method for generating reference currents in proportion to enable control of average power and extinction ratio of laser modulation in an optical transmitter
WO2020247859A3 (en) Tumor-associated antigen-specific t cell responses
WO2018112449A3 (en) Live cell imaging systems and methods to validate triggering of immune response
MX2015012768A (es) Sistemas y metodos de modulacion transposicional.
PH12019501356A1 (en) Metal-air fuel cell